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BACKGROUND
The cardiovascular effects of ertugliflozin, an inhibitor of sodium–glucose co-
transporter 2, have not been established.
METHODS
In a multicenter, double-blind trial, we randomly assigned patients with type 2 dia-
betes and atherosclerotic cardiovascular disease to receive 5 mg or 15 mg of ertug-
liflozin or placebo once daily. With the data from the two ertugliflozin dose 
groups pooled for analysis, the primary objective was to show the noninferiority of 
ertugliflozin to placebo with respect to the primary outcome, major adverse cardio-
vascular events (a composite of death from cardiovascular causes, nonfatal myo-
cardial infarction, or nonfatal stroke). The noninferiority margin was 1.3 (upper 
boundary of a 95.6% confidence interval for the hazard ratio [ertugliflozin vs. pla-
cebo] for major adverse cardiovascular events). The first key secondary outcome was 
a composite of death from cardiovascular causes or hospitalization for heart failure.
RESULTS
A total of 8246 patients underwent randomization and were followed for a mean 
of 3.5 years. Among 8238 patients who received at least one dose of ertugliflozin 
or placebo, a major adverse cardiovascular event occurred in 653 of 5493 patients 
(11.9%) in the ertugliflozin group and in 327 of 2745 patients (11.9%) in the pla-
cebo group (hazard ratio, 0.97; 95.6% confidence interval [CI], 0.85 to 1.11; 
P<0.001 for noninferiority). Death from cardiovascular causes or hospitalization 
for heart failure occurred in 444 of 5499 patients (8.1%) in the ertugliflozin group 
and in 250 of 2747 patients (9.1%) in the placebo group (hazard ratio, 0.88; 95.8% CI, 
0.75 to 1.03; P = 0.11 for superiority). The hazard ratio for death from cardiovascu-
lar causes was 0.92 (95.8% CI, 0.77 to 1.11), and the hazard ratio for death from 
renal causes, renal replacement therapy, or doubling of the serum creatinine level 
was 0.81 (95.8% CI, 0.63 to 1.04). Amputations were performed in 54 patients (2.0%) 
who received the 5-mg dose of ertugliflozin and in 57 patients (2.1%) who received 
the 15-mg dose, as compared with 45 patients (1.6%) who received placebo.
CONCLUSIONS
Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, 
ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular 
events. (Funded by Merck Sharp & Dohme and Pfizer; VERTIS CV ClinicalTrials.gov 
number, NCT01986881.)
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Cardiovascular disease is the lead-ing cause of illness and death in patients with type 2 diabetes.1-3 Type 2 diabetes is 
also a major risk factor for the development of 
heart failure and progression of renal disease.4,5 
Previous trials that evaluated the effects of so-
dium–glucose cotransporter 2 (SGLT2) inhibi-
tors on cardiovascular and kidney outcomes have 
shown consistent benefits with respect to cer-
tain outcomes such as hospitalization for heart 
failure and progression of renal disease.6-8
Ertugliflozin is an oral, selective SGLT2 inhibi-
tor that was approved by the Food and Drug Ad-
ministration (FDA) in the United States and by 
regulatory authorities in other countries for the 
improvement of glycemic control in adults with 
type 2 diabetes.9,10 The FDA has mandated that 
cardiovascular safety be evaluated in trials of new 
glucose-lowering drugs, including SGLT2 inhibi-
tors.11 The long-term effects of ertugliflozin on 
cardiovascular and renal outcomes were assessed 
in the Evaluation of Ertuglif lozin Efficacy and 
Safety Cardiovascular Outcomes Trial (VERTIS CV).
Me thods
Trial Design and Oversight
This multicenter, double-blind, randomized, pla-
cebo-controlled, event-driven, noninferiority trial 
involved patients with type 2 diabetes and estab-
lished atherosclerotic cardiovascular disease.12 
The protocol (available with the full text of this 
article at NEJM.org) was approved by the relevant 
regulatory authorities and ethics committees re-
sponsible for each trial site.
In collaboration with a group of academic 
investigators who comprised the scientific advi-
sory committee, representatives of the sponsors 
(Merck Sharp & Dohme [a subsidiary of Merck] 
and Pfizer) designed and oversaw the conduct of 
the trial. A clinical research organization, Parexel 
International, selected and monitored the trial 
sites and managed and stored the data, with 
oversight from the sponsors. An independent, 
external data and safety monitoring committee 
monitored the interim unblinded data. Lists of 
the trial committee members, investigators, and 
sites are provided in Section S1 in the Supple-
mentary Appendix, available at NEJM.org; infor-
mation regarding data handling and quality as-
surance is provided in Section S2.
Analyses were performed by employees of 
Parexel International, and the results were inde-
pendently confirmed by the sponsors with the 
use of original data. The academic authors ensured 
the accuracy and completeness of the data and 
were able to request additional analyses at their 
discretion. The first and last authors drafted the 
first version of the manuscript, and all the au-
thors contributed to revisions. The decision to 
submit the manuscript for publication was made 
jointly by the authors, who vouch for the com-
pleteness and accuracy of the data and for the 
fidelity of the trial to the protocol.
Protocol Revision
As reported previously,12 the original protocol was 
finalized in August 2013 and included a planned 
sample size of approximately 4000 patients. Af-
ter the results of the Empagliflozin Cardiovascu-
lar Outcome Event Trial in Type 2 Diabetes Mel-
litus Patients (EMPA-REG OUTCOME) became 
available,6 the protocol was amended in March 
2016 without knowledge of any interim results. 
The key changes were to double the sample size 
to approximately 8000 patients and to include 
efficacy objectives for superiority with respect to 
cardiovascular and renal outcomes. Patients who 
had been enrolled in the trial before the March 
2016 amendment were designated as cohort 1, 
and those who were enrolled after the March 2016 
amendment were designated as cohort 2.
Trial Population
A full list of the trial eligibility criteria is provided 
in Section S2. Patients were eligible if they were at 
least 40 years of age and had type 2 diabetes (with 
a glycated hemoglobin level of 7.0 to 10.5%) and 
established atherosclerotic cardiovascular disease 
involving the coronary, cerebrovascular, or periph-
eral arterial systems. Key exclusion criteria were a 
history of type 1 diabetes or ketoacidosis and an 
estimated glomerular filtration rate below 30 ml 
per minute per 1.73 m2 of body-surface area. All 
the patients provided written informed consent.
Trial Procedures
Eligible patients were randomly assigned in a 
1:1:1 ratio to receive 5 mg or 15 mg of ertugliflozin 
or matching placebo once daily, added to back-
ground standard-of-care treatment. Randomiza-
tion was performed at a central location with the 
use of an interactive voice-response system and 
was based on a computer-generated schedule with 
randomly permuted blocks, stratified according 
to geographic region. The rationale for the selec-
The New England Journal of Medicine 
Downloaded from nejm.org on October 29, 2020. For personal use only. No other uses without permission. 
 Copyright © 2020 Massachusetts Medical Society. All rights reserved. 
n engl j med 383;15 nejm.org October 8, 2020 1427
Cardiovascular Outcomes with Ertugliflozin in Diabetes
tion of the ertugliflozin dose and a detailed de-
scription of the randomization criteria are pro-
vided in Section S2.
Doses of background antihyperglycemic medi-
cation were held constant for the initial 18 weeks 
of the trial except in the patients who met the 
criteria for glycemic rescue (Section S3) and those 
with clinically significant hypoglycemia. Patients 
who discontinued ertugliflozin or placebo pre-
maturely were followed for outcomes, except if 
they withdrew consent or were lost to further 
follow-up. Extensive efforts were made to collect 
full outcome data from all the patients.
Trial Outcomes
The primary outcome, assessed in a time-to-event 
analysis, was a composite of death from cardio-
vascular causes, nonfatal myocardial infarction, 
or nonfatal stroke (i.e., a major adverse cardio-
vascular event). The key secondary outcomes, 
assessed in time-to-event analyses and in a hier-
archical statistical testing sequence, were a com-
posite of death from cardiovascular causes or 
hospitalization for heart failure; death from 
cardiovascular causes; and a composite of death 
from renal causes, renal replacement therapy, or 
doubling of the serum creatinine level. Addi-
tional outcomes and definitions are provided in 
Section S4. All the primary and secondary out-
come events were centrally adjudicated by a car-
diovascular adjudication committee in a blinded 
manner. The trial included three glycemic sub-
studies (results not reported here) (Section S5).
Changes from baseline in glycemic mea-
sures, body weight, and blood pressure were 
also assessed. Safety was assessed on the basis 
of adverse-event monitoring and, for certain ad-
verse events (e.g., genital mycotic infection, hy-
povolemia, and amputations), on the basis of a 
priori definitions (Section S6).
Statistical Analysis
Sample size and power for the analyses of the 
primary and key secondary outcomes have been 
described previously12; the original sample-size 
calculation before the March 2016 protocol revi-
sion is outlined in Section S7. For the final sam-
ple-size calculation, we estimated that, with a to-
tal of 8000 patients, 939 primary major adverse 
cardiovascular events would be accrued in ap-
proximately 6.1 years. With the data from the two 
ertugliflozin dose groups pooled for analysis, the 
trial had approximately 96% power to show non-
inferiority of ertugliflozin to placebo (the primary 
objective) by ruling out a hazard ratio for major 
adverse cardiovascular events of 1.3, in accordance 
with guidelines from the FDA; the power was 
determined under the assumption of no differ-
ence between the trial groups (i.e., hazard ratio 
for major adverse cardiovascular events of 1.0). If 
noninferiority was shown for the primary out-
come, then tests of superiority for the key second-
ary outcomes (a composite of death from cardio-
vascular causes or hospitalization for heart failure; 
death from cardiovascular causes; and a compos-
ite of death from renal causes, renal replacement 
therapy, or doubling of the serum creatinine level) 
were to be performed with the use of a sequen-
tially rejective graphical testing procedure.13
The noninferiority analysis of the primary 
outcome was performed with data from all the 
patients who had undergone randomization and 
received at least one dose of ertugliflozin or 
placebo. For the patients who discontinued the 
assigned trial regimen prematurely, only major 
adverse cardiovascular events that occurred up 
to 365 days after the confirmed last dose were 
included in the primary analysis, in accordance 
with guidance from the FDA. Tests of superior-
ity with respect to the secondary outcomes were 
performed on an intention-to-treat basis in all 
patients who had undergone randomization, 
with no limit on the time window for the ascer-
tainment of outcomes. These analyses were also 
performed according to cohort (cohort 1 vs. co-
hort 2). Sensitivity analyses were performed with 
the use of an intention-to-treat approach and an 
on-treatment approach, in which confirmed events 
that occurred between the day of the first dose 
of ertugliflozin or placebo and 14 days after the 
last dose were included in the analysis (Section S7).
One preplanned interim analysis had been 
scheduled to evaluate efficacy and futility with 
the use of a Lan–DeMets alpha-spending function 
with an O’Brien–Fleming boundary to control the 
type I error rate14; this analysis took place after 
715 major adverse cardiovascular events (73%) had 
accrued among the patients during treatment and 
up to 365 days after the last dose and after 351 
deaths from cardiovascular causes had accrued 
among the patients in the intention-to-treat popu-
lation. The trial was continued on the basis of 
the results of this interim analysis. The testing 
boundaries and confidence intervals for the final 
analyses were adjusted according to the actual 
alpha spent at the interim analysis (Section S7).
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A stratified Cox proportional-hazards model 
that included the trial group as a covariate and 
cohort of enrollment as the stratification factor 
was used to evaluate the primary outcome. After 
adjustment for the interim analysis, the upper 
boundary of a two-sided 95.6% confidence inter-
val for the hazard ratio was used for the nonin-
feriority test. The Kaplan–Meier method was 
used to estimate the cumulative incidence (first 
occurrence) of an outcome event over time in 
each trial group. Additional details are provided 
in Section S7.
The data from the two ertugliflozin dose 
groups were prespecified to be pooled for the 
assessment of cardiovascular and renal outcomes. 
Individual trial-group responses are presented 
for safety outcomes. Safety analyses included all 
patients who had undergone randomization and 
received at least one dose of ertugliflozin or 
placebo.
R esult s
Patients
From December 2013 through July 2015 and 
from June 2016 through April 2017, a total of 
8246 patients were enrolled in two cohorts 
(4023 patients in cohort 1 and 4223 patients in 
cohort 2). Patients were randomly assigned to 
receive ertuglif lozin (5499 patients) or placebo 
(2747 patients) and were followed at 567 cen-
ters in 34 countries (Fig. 1). The reasons that 
some patients did not proceed to randomiza-
tion after screening are listed in Table S1 in the 
Supplementary Appendix. A total of 8238 pa-
tients received at least one dose of ertuglif lozin 
or placebo and were included in the noninferi-
ority analysis of the primary outcome and in 
the analysis of safety.
The baseline characteristics of the patients 
were well balanced between the ertugliflozin 
group and the placebo group (Table 1). The mean 
age of the patients was 64.4 years, the mean dura-
tion of diabetes was 13.0 years, and the mean 
glycated hemoglobin level was 8.2%. Coronary 
artery disease was present in 75.9% of the patients, 
cerebrovascular disease in 22.9%, and peripheral 
arterial disease in 18.7%; a total of 23.7% had a 
history of heart failure. Use of cardiovascular 
and antihyperglycemic medications was largely 
balanced between the trial groups at baseline and 
also at the end of the trial, with the exception of 
diuretics, which were used more often in the 
placebo group than in the ertugliflozin group at 
the end of the trial (Table S2).
Follow-up
The final follow-up window was from September 
2019 through December 2019; the last patient 
visit took place on December 27, 2019. The mean 
duration of follow-up was 3.5 years (4.3 years in 
cohort 1 and 2.7 years in cohort 2), and the 
corresponding median duration was 3.0 years 
(4.6 years in cohort 1 and 2.7 years in cohort 2). 
Ertugliflozin was administered over a mean pe-
riod of 2.9 years, and placebo over a mean peri-
od of 2.8 years (Table S3). The trial regimen was 
permanently discontinued before trial comple-
tion — for reasons other than death — by 23.5% 
of the patients in the ertugliflozin group and by 
27.9% of the patients in the placebo group (Table 
S4). Final vital status was known for 99.3% of 
the patients.
Cardiovascular and Renal Outcomes
A major adverse cardiovascular event (the pri-
mary outcome) occurred in 653 of 5493 patients 
(11.9%) in the ertugliflozin group and in 327 of 
2745 patients (11.9%) in the placebo group (haz-
ard ratio, 0.97; 95.6% confidence interval [CI], 
0.85 to 1.11; P<0.001 for noninferiority) (Fig. 2A 
and Table 2). Death from cardiovascular causes 
or hospitalization for heart failure (the first key 
secondary outcome) occurred in 444 of 5499 
patients (8.1%) in the ertugliflozin group and in 
250 of 2747 patients (9.1%) in the placebo group 
(hazard ratio, 0.88; 95.8% CI, 0.75 to 1.03; 
P = 0.11 for superiority) (Fig. 2B and Table 2). 
With respect to the other key secondary out-
comes, the hazard ratio (ertugliflozin vs. placebo) 
for death from cardiovascular causes was 0.92 
(95.8% CI, 0.77 to 1.11) (Fig. 2C and Table 2), 
and the hazard ratio for death from renal causes, 
renal replacement therapy, or doubling of the 
serum creatinine level was 0.81 (95.8% CI, 0.63 
to 1.04) (Fig. 2D and Table 2).
The results for the other secondary outcomes 
that were not included in the testing hierarchy 
are provided in Table 2. The hazard ratio (ertug-
liflozin vs. placebo) for hospitalization for heart 
failure was 0.70 (95% CI, 0.54 to 0.90) (Table 2 
and Fig. S1), and the hazard ratio for death from 
any cause was 0.93 (95% CI, 0.80 to 1.08). The 
results of sensitivity analyses (Tables S5 through 
S7) were generally consistent with those shown 
in Table 2. The results were also generally con-
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sistent across subgroups with regard to the pri-
mary outcome (Fig. S2) and the composite out-
come of death from cardiovascular causes or 
hospitalization for heart failure (Fig. S3). The 
results for the two ertugliflozin dose groups, as 
compared with the placebo group, are provided 
in Figure S4 and Table S8.
Metabolic Results
At week 18, the least-squares mean difference from 
baseline in the glycated hemoglobin level was 
–0.70% (95% CI, –0.73 to –0.67) among the pa-
tients who received the 5-mg dose of ertugliflozin, 
–0.72% (95% CI, –0.75 to –0.69) among those who 
received the 15-mg dose of ertugliflozin, and 
–0.22% (95% CI, –0.25 to –0.19) among those 
who received placebo. The least-squares mean 
changes from baseline in glycated hemoglobin 
level, body weight, and systolic blood pressure 
over the trial period are shown in Figures S5 
through S7. At 1 year, body weight had decreased 
by a mean (±SD) of 2.4±3.9 kg with the 5-mg 
Figure 1. Screening, Randomization, and Follow-up.
Patients were counted only once in the calculation of the total number of patients who did not meet eligibility crite‑
ria, although a patient may be listed for more than one reason.
8246 Were included in the
intention-to-treat population
14,605 Patients were assessed for eligibility
6355 Were not eligible
6350 Did not meet eligibility criteria
3549 Did not meet inclusion criteria for
glycated hemoglobin level
1281 Met laboratory exclusion criteria
1134 Met thyroid-related exclusion
criteria
358 Had potential adherence issues
331 Did not meet inclusion criteria
for atherosclerosis
1025 Did not meet other inclusion 
criteria or met other exclusion
criteria
5 Had other reason
8250 Underwent randomization
4 Were excluded
2 Were enrolled twice in the trial
2 Were concurrently enrolled in another
trial of ertugliflozin
2747 Were assigned to receive
placebo
2 Did not receive any doses
2389 (87.0%) Completed the trial
111 (4.0%) Withdrew from
the trial prematurely
767 (27.9%) Discontinued 
placebo prematurely
254 (9.2%) Died
2730 (99.4%) Had vital status
available
2747 Were assigned to receive
ertugliflozin, 15 mg/day
2401 (87.4%) Completed the trial
113 (4.1%) Withdrew from
the trial prematurely
656 (23.9%) Discontinued 
ertugliflozin prematurely
238 (8.7%) Died
2727 (99.3%) Had vital status
available
2752 Were assigned to receive
ertugliflozin, 5 mg/day
6 Did not receive any doses
2422 (88.0%) Completed the trial
102 (3.7%) Withdrew from
the trial prematurely
635 (23.1%) Discontinued 
ertugliflozin prematurely
235 (8.5%) Died
2730 (99.2%) Had vital status
available
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Table 1. Demographic and Clinical Characteristics of the Patients at Baseline.*
Characteristic
Ertugliflozin 
(N = 5499)†
Placebo 
(N = 2747)
Age — yr 64.4±8.1 64.4±8.0
Male sex — no. (%) 3866 (70.3) 1903 (69.3)
Race — no. (%)‡
White 4826 (87.8) 2414 (87.9)
Black 166 (3.0) 69 (2.5)
Asian 336 (6.1) 162 (5.9)
Other 171 (3.1) 102 (3.7)
Region — no. (%)
North America 1208 (22.0) 605 (22.0)
South America 484 (8.8) 239 (8.7)
Europe 3091 (56.2) 1546 (56.3)
Asia 350 (6.4) 173 (6.3)
South Africa 251 (4.6) 126 (4.6)
Australia and New Zealand 115 (2.1) 58 (2.1)
Body‑mass index§ 31.9±5.4 32.0±5.5
Duration of type 2 diabetes — yr¶ 12.9±8.3 13.1±8.4
Glycated hemoglobin — %‖ 8.2±1.0 8.2±0.9
Total cholesterol — mg/dl** 168.9±46.9 168.3±45.5
Low‑density lipoprotein cholesterol — mg/dl†† 89.3±38.5 88.8±37.7
High‑density lipoprotein cholesterol — mg/dl‡‡ 43.7±12.0 43.9±12.3
Triglycerides — mg/dl§§ 181.4±119.2 178.9±104.7
Blood pressure — mm Hg¶¶
Systolic 133.5±13.7 133.1±13.9
Diastolic 76.8±8.3 76.4±8.7
Estimated GFR — ml/min/1.73 m2‖‖
Mean value 76.1±20.9 75.7±20.8
Value of <60 ml/min/1.73 m2 — no. (%) 1199 (21.8) 608 (22.1)
Coronary artery disease — no. (%) 4144 (75.4) 2112 (76.9)
Cerebrovascular disease — no. (%) 1276 (23.2) 613 (22.3)
Peripheral arterial disease — no. (%) 1029 (18.7) 512 (18.6)
Heart failure — no. (%) 1286 (23.4) 672 (24.5)
Myocardial infarction — no. (%) 2625 (47.7) 1329 (48.4)
Coronary revascularization — no. (%) 3179 (57.8) 1612 (58.7)
Coronary‑artery bypass graft 1223 (22.2) 599 (21.8)
Percutaneous coronary intervention 2301 (41.8) 1184 (43.1)
Stroke — no. (%) 1181 (21.5) 558 (20.3)
*  Plus–minus values are means ±SD. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. To con‑
vert the values for triglycerides to millimoles per liter, multiply by 0.01129. Percentage may not total 100 because of rounding.
†  The data from the patients who received the 5‑mg dose of ertugliflozin and from those who received the 15‑mg dose 
were pooled.
‡  Race was reported by the patients.
§  Body‑mass index is the weight in kilograms divided by the square of the height in meters. Data were available for 
5496 patients in the ertugliflozin group and 2747 patients in the placebo group.
¶  Data were available for 5493 patients in the ertugliflozin group and 2745 patients in the placebo group.
‖  Data were available for 5474 patients in the ertugliflozin group and 2732 patients in the placebo group.
**  Data were available for 5412 patients in the ertugliflozin group and 2703 patients in the placebo group.
††  Data were available for 5407 patients in the ertugliflozin group and 2698 patients in the placebo group.
‡‡  Data were available for 5411 patients in the ertugliflozin group and 2704 patients in the placebo group.
§§  Data were available for 5474 patients in the ertugliflozin group and 2734 patients in the placebo group.
¶¶  Data were available for 5481 patients in the ertugliflozin group and 2740 patients in the placebo group.
‖‖  The estimated glomerular filtration rate (GFR) was calculated with the Modification of Diet in Renal Disease equa‑
tion. Data were available for 5498 patients in the ertugliflozin group and 2747 patients in the placebo group.
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dose of ertugliflozin and by 2.8±4.0 kg with the 
15-mg dose of ertugliflozin, as compared with 
0.4±3.6 kg with placebo.
Safety Outcomes
The incidence of serious adverse events and ad-
verse events leading to permanent discontinua-
tion of the trial regimen did not differ signifi-
cantly between either ertugliflozin dose group and 
the placebo group (Table 3 and Table S9). More 
urinary tract infections and genital mycotic in-
fections were reported in each of the ertugliflozin 
dose groups than in the placebo group. No cases 
of Fournier’s gangrene were reported in any 
group. The incidence of serious acute kidney in-
jury, serious urinary tract infection, hypovolemia, 
Figure 2. Primary and Key Secondary Outcomes.
Shown are Kaplan–Meier curves of the cumulative incidence (first occurrence) of a major adverse cardiovascular event, defined as a com‑
posite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke (the primary outcome) (Panel A), and of key 
secondary outcome events that included a composite of death from cardiovascular causes or hospitalization for heart failure (Panel B), death 
from cardiovascular causes (Panel C), and a composite renal outcome event (death from renal causes, renal replacement therapy, or dou‑
bling of the serum creatinine level) (Panel D). The insets in each panel show the same data on an enlarged y axis. The noninferiority analysis 
of the primary outcome was performed with data from all the patients who had undergone randomization and received at least one dose of 
ertugliflozin (5493 patients) or placebo (2745 patients). For patients who discontinued the trial regimen prematurely, only major adverse car‑
diovascular events that occurred up to 365 days after the confirmed last dose were included in the primary analysis. The superiority analyses 
of the key secondary outcomes were performed on an intention‑to‑treat basis with data from all the patients who had undergone randomiza‑
tion to receive ertugliflozin (5499 patients) or placebo (2747 patients), with no limit on the time window for the ascertainment of outcomes.
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fractures, or symptomatic or severe hypoglycemia 
did not differ significantly between either ertug-
liflozin dose group and the placebo group.
Amputations were performed in 54 patients 
(2.0%) who received the 5-mg dose of ertugli-
flozin and in 57 patients (2.1%) who received the 
15-mg dose, as compared with 45 patients (1.6%) 
who received placebo (Table S10). Diabetic keto-
acidosis occurred in 7 patients (0.3%) who received 
the 5-mg dose of ertugliflozin and in 12 patients 
(0.4%) who received the 15-mg dose, as compared 
with 2 patients (0.1%) who received placebo.
Discussion
In this trial involving patients with type 2 diabetes 
and established atherosclerotic cardiovascular 
disease, ertugliflozin, when added to guideline-
directed secondary prevention therapies, was 
shown to be noninferior to placebo with respect 
to major adverse cardiovascular events. The inci-
dence of death from cardiovascular causes or 
hospitalization for heart failure (the first key 
secondary composite outcome) did not differ 
significantly between the trial groups; therefore, 
in accordance with the prespecified hierarchical 
testing procedure, further statistical testing of 
other outcomes was not performed.
We do not have a clear explanation about why 
our results did not reach significance, whereas 
significance was reached for many (but not all) 
end points in previous cardiovascular outcomes 
trials of SGLT2 inhibitors.6-8 Our trial population 
of patients with atherosclerotic cardiovascular 
disease was broadly similar to those in previous 
trials, with rates of major adverse cardiovascular 
events of approximately 4% per year. In VERTIS 
CV, as compared with previous trials, the doses 
used were pharmacologically similar with regard 
to SGLT2 inhibition and the pharmacodynamic 
effects observed were similar with regard to the 
effects on glycated hemoglobin level, body weight, 
and blood pressure. However, differences exist 
among the trials, which might explain some dif-
ferences in outcomes. Secular trends of more 
intensive secondary preventive therapies over 
recent years could have had a greater effect in 
our trial than in earlier trials. The selectivity of 
ertugliflozin for SGLT2 over SGLT1 is high and 
is similar to that of empagliflozin,15 but we can-
not exclude the possibility that differences 
among the agents in this class may result in real 
differences in outcomes. It is also possible that 
the effects of the individual agents are actually 
similar; the confidence intervals in VERTIS CV 
overlap those in previous trials.
Although the secondary outcome of hospital-
ization for heart failure was not tested statisti-
cally, the hazard ratio and confidence interval, 
as well as the time course of these adjudicated 
events, are consistent with the effects observed 
in previous trials of SGLT2 inhibitors.6-8 In con-
trast, no significant benefit of ertugliflozin was 
observed for the renal composite outcome (death 
from renal causes, renal replacement therapy, or 
doubling of the serum creatinine level) in VERTIS 
CV, whereas previous trials of other SGLT2 in-
hibitors have shown consistent reductions in the 
risk of both albuminuria and clinical renal com-
posite outcomes.7,8,16 Moreover, in the CREDENCE 
(Canagliflozin and Renal Events in Diabetes with 
Established Nephropathy Clinical Evaluation) trial 
involving patients with type 2 diabetes, macroal-
buminuria (defined as a urinary albumin-to-cre-
atinine ratio of >300 to 5000, with albumin 
measured in milligrams and creatinine in grams), 
and an estimated glomerular filtration rate of 
30 to less than 90 ml per minute per 1.73 m2, 
the relative risk of the primary outcome (a com-
posite of end-stage kidney disease, a doubling of 
the serum creatinine level, or death from renal 
or cardiovascular causes) was 30% lower with 
canagliflozin than with placebo.17 Definitions of 
renal end points differ across trials, so further 
analyses of our trial with the use of these differ-
ent end points are warranted.
The adverse events seen with ertugliflozin were 
consistent with the known risks of the medicines 
in the SGLT2 inhibitor class. As expected, genital 
mycotic infections occurred more frequently among 
women and among men in either ertugliflozin dose 
group than among those in the placebo group. The 
percentage of patients who underwent amputa-
tion was numerically — but not significantly 
— higher in either ertugliflozin dose group than 
in the placebo group, and the percentage of pa-
tients who had diabetic ketoacidosis was higher 
in either ertugliflozin dose group than in the pla-
cebo group (statistical testing was not performed).
In this multicenter, double-blind, randomized, 
controlled trial involving patients with type 2 
diabetes and atherosclerotic cardiovascular dis-
ease, ertugliflozin was shown to be noninferior 
to placebo with respect to the composite out-
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come of death from cardiovascular causes, non-
fatal myocardial infarction, or nonfatal stroke.
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